RVOT prestenting prior to Melody valve implantation reduced the incidence of stent fractures compared to no prestenting (16.7% vs 33.5%; OR 0.39, 95% CI 0.22-0.69).
Meta-Analysis (n=360)
Does RVOT prestenting prevent Melody valve stent fractures in patients undergoing transcatheter pulmonary valve implantation?
RVOT prestenting prior to Melody valve implantation significantly reduces the risk of stent fractures and the need for fracture-related reinterventions.
Odds Ratio: 0.39 (95% CI 0.22–0.69)
Absolute Event Rate: 16.7% vs 33.5%
INTRODUCTION: The role of right ventricular outflow tract (RVOT) prestenting in the prevention of Melody valve stent fractures (SFs) is not well defined. We aimed to perform a systematic review and meta-analysis comparing the incidence of SF in Melody valve transcatheter pulmonary implants with and without prestenting. METHODS: PubMed, EMBASE, and Cochrane Central were searched for studies that reported the incidence of SF in Melody valve transcatheter pulmonary implants stratified by the presence or absence of RVOT prestenting. Subgroup analyses were performed for (1) SF associated with a loss of stent integrity and (2) SF requiring reintervention. RESULTS: Five studies and 360 patients were included, of whom 207 (57.5%) received prestenting. Follow-up ranged from 15 to 30 months. SF were significantly reduced in the prestenting group (16.7%) when compared to no prestenting (33.5%) (odds-ratio OR 0.39; 95%CI 0.22-0.69). Patients who received prestenting also had a lower incidence of (1) SF associated with loss of stent integrity (OR 0.16; 95%CI 0.05-0.48) and (2) SF requiring reintervention (OR 0.15; 95%CI 0.02-0.91). CONCLUSION: Our findings suggest that stenting of the RVOT prior to Melody valve implantation is associated with a reduction in the incidence of SF and fracture-related reinterventions.
Cardoso et al. (Tue,) conducted a meta-analysis in Melody valve transcatheter pulmonary implants (n=360). Right ventricular outflow tract (RVOT) prestenting vs. No prestenting was evaluated on Incidence of stent fractures (SF) (OR 0.39, 95% CI 0.22-0.69). RVOT prestenting prior to Melody valve implantation reduced the incidence of stent fractures compared to no prestenting (16.7% vs 33.5%; OR 0.39, 95% CI 0.22-0.69).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: